Leonid Timashev

Q: How accurate are Leonid Timashev's stock ratings?

About 59% of Leonid's ratings were profitable over a one-year hold, with an average return of +4.3% per rating, measured by 13Foresight from historical prices.

Q: How is Leonid ranked?

Leonid Timashev is ranked #683 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

RBC Capital

Wall Street Analyst

★★★★☆

#683

on 13Foresight · ranked by our own returns

57%

Success Rate

+4.2%

Average Return

45 of 79 calls profitable · +2.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 57% of Leonid Timashev's ratings turned a profit when each position was held for 1 year — averaging +4.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

238 Buy 32 Hold 0 Sell

Leonid's Stock Coverage 26 ratings · 2026-08-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
LEGN Legend Biotech	Aug 11, 2026	BUY	Strong Buy +199.8% avg upside 27 analysts	$58.00 180.88% Upside	-7.1%	·
BHVN Biohaven Ltd.	Aug 10, 2026	BUY	Strong Buy +59.7% avg upside 25 analysts	$23.00 59.83% Upside	+2.1%	·
AXSM Axsome Therapeutics	Aug 10, 2026	BUY	Strong Buy +10.1% avg upside 29 analysts	$297.00 38.29% Upside	-3.3%	·
JAZZ Jazz Pharmaceuticals	Aug 10, 2026	BUY	Strong Buy -5.1% avg upside 35 analysts	$273.00 9.76% Upside	-4.2%	·
CATX Perspective Therapeutics	Aug 10, 2026	BUY	Strong Buy +244.3% avg upside 22 analysts	$14.00 329.45% Upside	+3.3%	·
CYTK Cytokinetics	Aug 07, 2026	BUY	Strong Buy +17.8% avg upside 36 analysts	$112.00 48.02% Upside	-4.3%	·
EXEL Exelixis	Aug 06, 2026	HOLD	Buy -14.3% avg upside 34 analysts	$46.00 8.79% Downside	-3.0%	·
INSM Insmed	Aug 06, 2026	BUY	Strong Buy +33.7% avg upside 37 analysts	$195.00 47.44% Upside	-4.7%	·
VSTM Verastem	Aug 06, 2026	BUY	Strong Buy +118.8% avg upside 24 analysts	$14.00 101.53% Upside	+14.4%	·
NUVB Nuvation Bio	Aug 06, 2026	BUY	Strong Buy +109.8% avg upside 15 analysts	$20.00 211.54% Upside	+0.0%	·
PRAX Praxis Precision Medicines	Aug 06, 2026	BUY	Strong Buy +42.1% avg upside 24 analysts	$462.00 19.65% Upside	-0.5%	·
EWTX Edgewise Therapeutics	Aug 06, 2026	BUY	Strong Buy +3.6% avg upside 15 analysts	$59.00 35.43% Upside	-2.8%	·
CGON CG Oncology, Inc.	Aug 06, 2026	BUY	Strong Buy +11.6% avg upside 17 analysts	$79.00 2.68% Upside	+2.2%	·
ONC BeOne Medicines	Aug 05, 2026	BUY	Strong Buy +1.0% avg upside 28 analysts	$450.00 25.35% Upside	+8.7%	·
RVMD Revolution Medicines	Aug 05, 2026	BUY	Strong Buy -17.7% avg upside 32 analysts	$203.00 1.10% Downside	+2.4%	·
CMPS COMPASS Pathways	Aug 05, 2026	BUY	Strong Buy +57.6% avg upside 20 analysts	$21.00 47.65% Upside	-2.1%	·
NAMS NewAmsterdam Pharma Company	Aug 05, 2026	BUY	Strong Buy +71.2% avg upside 19 analysts	$50.00 79.60% Upside	-2.7%	·
XNCR Xencor	Aug 05, 2026	BUY	Strong Buy +50.6% avg upside 27 analysts	$20.00 13.79% Downside	+15.9%	·
IDYA IDEAYA Biosciences	Aug 04, 2026	BUY	Strong Buy +31.3% avg upside 29 analysts	$48.00 29.97% Upside	+1.6%	·
DSGN Design Therapeutics	Aug 03, 2026	BUY	Strong Buy +25.1% avg upside 9 analysts	$20.00 36.40% Upside	+12.8%	·
BCYC Bicycle Therapeutics	Jul 30, 2026	HOLD	Strong Buy +476.1% avg upside 21 analysts	$5.00 23.15% Upside	-0.8%	·
ALKS Alkermes	Jul 28, 2026	BUY	Strong Buy -17.2% avg upside 34 analysts	$56.00 11.32% Upside	-2.1%	·
CRMD Cormedix	Jul 07, 2026	BUY	Strong Buy +108.1% avg upside 13 analysts	$13.00 83.19% Upside	-16.1%	·
PYXS Pyxis Oncology	Jul 07, 2026	BUY	Strong Buy +146.7% avg upside 14 analysts	$5.00 57.27% Upside	-1.9%	·
ADCT ADC Therapeutics	Jul 07, 2026	HOLD	Buy +401.5% avg upside 12 analysts	$2.00 62.66% Upside	-8.9%	·
JSPR Jasper Therapeutics	May 14, 2026	HOLD	Strong Buy +3394.0% avg upside 18 analysts	$3.00 264.15% Upside	-10.4%	·

🔒 21 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Leonid Timashev — Frequently Asked Questions

How accurate are Leonid Timashev's stock ratings?

Based on the calls 13Foresight could measure, about 59% of Leonid's ratings were profitable over a one-year hold, with an average return of +4.3% per rating, or +2.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Leonid ranked on 13Foresight?

Leonid Timashev is currently ranked #683 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Leonid cover?

Leonid most recently has ratings on LEGN, BHVN, AXSM, JAZZ, CATX, CYTK, EXEL, INSM, VSTM, NUVB, PRAX, EWTX and 14 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Leonid Timashev

Rating Distribution

Welcome to 13Foresight!